HIV Treatment Bulletin - October 2003
Simon Collins, HIV i-Base

Early results from the large international ESPRIT study presented to the IAS conference this summer confirmed the ability of several courses of IL-2 to dramatically increase CD4 counts. However, IL-2 is associated with difficult side effects during the five-day administration periods including moderate to severe fatigue, myalgia and fever in up to 90% of subjects.

These symptoms are thought to be proinflammatory responses related to elevations in tumour-necrosis facto-alpha (TNF-α) and IL-6 that occur with IL-2 treatment. As corticosteroids inhibit production of TNF-α, a small pilot study looked at whether prednisone could reduce the side effects without reducing CD4 increases.

Dr Jorge Tavel and colleagues from NIAID randomised 19 patients to one of four treatment groups (A-D): IL-2 + placebo (A), IL-2 + prednisone (B), prednisone alone (C) and placebo alone (D). Five patients were in each arm except the placebo arm, which had four patients. IL-2 was dosed at 7.5 MIU sc BID for each five day cycle, with cycles repeated every two months. Prednisone was dosed at 0.5mg/kg/day orally for seven days every two months, coinciding with the administration of IL-2.

Increases in CD4 count were 452, 110, 27 and 135 in groups A, B, C and D respectively. All subjects in group A showed significant CD4 increases, but concomitant use of prednisone blunted or in some cases prevented this in subjects in group B.

Although higher toxicity was reported in group A compared to B the researchers question whether these differences were significant. No difference in fatigue or dose reductions of IL-2 were reported between the groups A and B, although temperature was 0.4°C lower in those patients receiving prednisone.

Although prednisone decreased levels of proinflammatory cytokines during IL-2 cycles, these responses appear to be critical to IL-2 induced CD4 increases.

The authors conclude that IL-2 dose reduction in combination with use of nonsteroidal agents, is the best approach to manage toxicity and maximise response.

Ref: Tavel JA, Sereti I, Walker RE et al. A randomised, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J Infect Dis. 2003 Aug 15;188(4):531-6.

031010
IB30408-24

©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.